Sequential CD19/CD22 CAR-T Cell Therapy Shows Promise in Treating Large B-Cell Lymphoma
Recent studies have shown that sequential CD19/CD22 CAR-T cell therapy, when used following autologous stem cell transplantation (ASCT), improves efficacy in treating relapsed/refractory large B-cell lymphoma (LBCL) compared to CAR-T therapy alone. This approach, known as cocktail therapy, targets multiple antigens simultaneously, which helps prevent tumor recurrence due to antigen escape. The therapy has demonstrated feasibility and safety, offering a potential new treatment paradigm for patients with malignant B-cell hematologic neoplasms. 
